Review of medications used in juvenile rheumatoid arthritis

Pediatric Emergency Care

Volumn 23, Issue 1, 2007, Pages 38-46

  Guthrie, Bridgette ^a,c   Rouster Stevens, Kelly A ^b   Reynolds, Sally L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Box 62 ^*  (United States)

Author keywords

Juvenile rheumatoid arthritis; Medication; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; CELECOXIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DICLOFENAC; ETANERCEPT; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; INFLIXIMAB; KETOPROFEN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; SULINDAC; THALIDOMIDE; TOLMETIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ALLERGIC PNEUMONITIS; ALOPECIA; ANALGESIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CELLULITIS; CLINICAL TRIAL; CONJUNCTIVITIS; CROHN DISEASE; DEMYELINATING DISEASE; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DISEASE CONTROL; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EMERGENCY MEDICINE; ENZYME INHIBITION; ESOPHAGITIS; FIBROSING ALVEOLITIS; FLU LIKE SYNDROME; GASTRITIS; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; HAIR LOSS; HEADACHE; HEPATITIS; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INFECTION; INFECTION COMPLICATION; INJECTION SITE REACTION; INTERSTITIAL NEPHRITIS; JOINT CHARACTERISTICS AND FUNCTIONS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FIBROSIS; LIVER CIRRHOSIS; LIVER TOXICITY; LUNG DISEASE; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; LYMPHOMA; MACROCYTIC ANEMIA; MACROPHAGE ACTIVATION; MOUTH ULCER; MYOPATHY; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; OTITIS; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PATHOPHYSIOLOGY; PEPTIC ULCER; PERIPHERAL NEUROPATHY; PHARYNGITIS; PNEUMONIA; PSEUDOPORPHYRIA; RASH; REVIEW; REYE SYNDROME; SEPSIS; SIDE EFFECT; SKIN DISEASE; SKIN INFECTION; SKIN TINGLING; STEVENS JOHNSON SYNDROME; STOMACH DISEASE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UVEITIS; VASCULITIS; VOMITING; WEIGHT GAIN;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 33846274915     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e31802c61ae     Document Type: Review

References (71)

1. Peterson LS, Mason T, Nelson AM, et al. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993. Is the epidemiology changing? Arthritis Rheum. 1996;39:1385-1390.
2. Brewer EJ Jr, Bass J, Baum J, et al. Current proposed revision of JRA criteria. Arthritis Rheum. 1977;20(suppl):195-199.
3. Cassidy J, Petty R. Juvenile rheumatoid arthritis. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:272.
4. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:94.
5. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:92.
6. Simon L. NSAIDs: mechanism of Action. In: Rose BD, ed. UpToDate. Wellesley, MA: UpToDate; 2004.
7. Lovell DJ, Giannini EH, Brewer EJ. Time course of response to nonsteroidal antiinflammatory drugs in juvenile rheumatoid arthritis. Arthritis Rheum. 1984;27:1433-1437.
8. Duffy CM, Gibbon M, Yang H, et al. Non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity in a practice-based cohort of children with juvenile arthritis. J Rheumatol. 2000;27(suppl 58):73.
9. Keenan GF, Giannini EH, Athreya BH. Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol. 1995;22:1149-1151.
10. Henry D, Lim L, Garcia Rodriquez L, et al. Variability in risk of gastrointestinal complications with individual non-steroidal antiinflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312:1563-1566.
11. Feldman M. NSAIDs: prevention and treatment of gastroduodenal toxicity. In: Rose BD, ed. UpToDate. Wellesley, MA: UpToDate; 2004
12. Gazarian M, Berkovitch M, Koren G, et al. Experience with misoprostol therapy for NSAID gastropathy in children. Ann Rheum Dis. 1995;54:277-280.
13. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:98.
14. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:93.
15. Kremer JM. Use of methotrexate in rheumatoid arthritis. In: Rose BD, ed. UpToDate. Wellesley, MA: UpToDate; 2004
16. Alsufyani K, Ortiz-Alvarez O, Cabral D, et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004;31:179-182.
17. Giannini E, Brewer E, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. results of the USA-USSR double-blind, placebo-controlled trial. N Engl J Med. 1992;326:1043-1049.
18. Ilowite N. Current treatment of juvenile rheumatoid arthritis. Pediatrics. 2002;109:109-115.
19. Hashkes P, Balistreri W, Bove K, et al. The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1997;40:2226-2234.
20. Acute Leukemia Group B. Acute lymphocytic leukemia in children. Maintenance therapy with methotrexate administered intermittently. JAMA. 1969;207:923.
21. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:110.
22. van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998;41:808-816.
23. Ansell BM, Hall MA, Loftus JK, et al. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol. 1991;9:201-203.
24. Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol. 1996;23:360-366.
25. Silverman E, Spiegel L, Hawkins D, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52:554-562.
26. Smolen J, Kalden J, Scott D, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet. 1999;353:259-266.
27. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542-2550.
28. Emery P, Breedveld F, Lemmel E, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Multinational Leflunomide Study Group. Rheumatology. 2000;39:655-665.
29. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:116.
30. In: Pickering L, ed. 2003 Redbook: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003.
31. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:117.
32. van Vugt RM, Sijbrandij ES, Bijlsma JW. Magnetic resonance imaging of the femoral head to detect avascular necrosis in active rheumatoid arthritis treated with methylprednisolone pulse therapy. Scand J Rheumatol. 1996;25(2):74-76.
33. Conn H, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619-632.
34. Adebajo A, Hall M. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheum. 1998;37:1240-1242.
35. Job-Deslandre C, Menkes C. Administration of methylprednisolone pulse in chronic arthritis in children. Clin Exp Rheum. 1991;9:15-18.
36. Padeh S, Passwell J. Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum. 1998;41:1210-1214.
37. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:129.
38. Lovell D, Giannini E, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763-769.
39. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003;62:245-247.
40. Haapasaari J, Kautiainen H, Hannula S, et al. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20:867-870.
41. Quartier P, Taupin P, Bourdeaut F. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093-1101.
42. ten Cate R, van Suijlekom-Smit L, Brinkman D, et al. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis. Rheumatology. 2002;41:228-229.
43. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44:1411-1415.
44. Lovell D, Giannini E, Reiff A. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003;48:218-226.
45. Mohan A, Coté T, Block J, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39:295-299.
46. Prahalad S, Bove K, Dickens D, et al. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol. 2001;28:2120-2124.
47. Livermore P, Murray K. Anti-tumour necrosis factory therapy associated with cutaneous vasculitis. Rheumatology. 2002;41:1450-1452.
48. Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2000;43:2381-2382.
49. Lepore L, Marchetti F, Facchini S, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2003;21:276-277.
50. Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 1999;29:148-158.
51. Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther. 2004;6:S12-S18.
52. Gerloni V, Lurati A, Gattinara M, et al. Efficacy of infusions of an anti-TNF antibody (infliximab) in persistently active refractory juvenile idiopathic arthritis: results of a two year open label prospective study [abstract]. Arthritis Rheum. 2003;48(suppl):S92.
53. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
54. St. Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451-1459.
55. Lovell DJ, Ruperto N, Goodman S, et al. Preliminary data from the study of adalimumab in children with juvenile idiopathic arthritis (JIA) (abstract). Arthritis Rheum. 2004;50(suppl):S436.
56. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2071-2075.
57. Irigoyen PI, Olson J, Hom C, et al. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra [abstract]. Arthritis Rheum. 2004;50(suppl):S437.
58. Henrickson M. Efficacy of anakinra in refractory systemic arthritis [abstract]. Arthritis Rheum. 2004;50(suppl):S438.
59. Bresnihan B, Cunnane G. Interleukin-1 receptor antagonist. Rheum Dis North Am. 1998;24:615-628.
60. Fleishmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48:927-934.
61. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:124.
62. Lin Y, Yang Y, Tsai M, et al. Long-term effects of azathioprine therapy for juvenile rheumatoid arthritis. J Formos Med Assoc. 2000;99:330-335.
63. Savolainen H, Kautiainen H, Isomaki H, et al. Azathioprine in patients with juvenile chronic arthritis: a long-term followup study. J Rheumatol. 1997;24:2444-2450.
64. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:125.
65. Chen C, Chen L, Yeh K, et al. Sequential changes to clinical parameters and adhesion molecules following intravenous pulse cyclophosphamide and methylprednisolone treatment of refractory juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004;22:259-264.
66. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemiconset juvenile rheumatoid arthritis. Arthritis Rheum. 1997;40:1852-1855.
67. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:126.
68. Laxer R, Gazarian M. Pharmacology and drug therapy. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. Philadelphia, PA: WB Saunders Co; 2001:127.
69. Gerloni V, Cimaz R, Gattinara M, et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Result of a 10-year prospective study. Rheumatology. 2001;40:907-913.
70. Lehman T, Schechter S, Sundel R, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr. 2004;145:856-857.
71. Zeldis J, Williams B, Thomas S, et al. STEPS: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999;21:319-330.